| WB | 咨询技术 | Human,Mouse,Rat |
| IF | 咨询技术 | Human,Mouse,Rat |
| IHC | 咨询技术 | Human,Mouse,Rat |
| ICC | 技术咨询 | Human,Mouse,Rat |
| FCM | 1/200 - 1/400 | Human,Mouse,Rat |
| Elisa | 1/10000 | Human,Mouse,Rat |
| Aliases | CLEC9A; DNGR1; DNGR-1; UNQ9341 |
| Entrez GeneID | 283420 |
| clone | 5C7A7 |
| WB Predicted band size | 27.3kDa |
| Host/Isotype | Mouse IgG2b |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Human |
| Immunogen | Purified recombinant fragment of human CD370 (AA: extra 57-241) expressed in E. Coli. |
| Formulation | Purified antibody in PBS with 0.05% sodium azide |
+ +
以下是关于CD370(CLEC9A)抗体的3篇代表性文献，简要概括如下：
1. **文献名称**：*Targeting CLEC9A delivers antigen to human CD141+ dendritic cells for anti-cancer immunity*
**作者**：Sancho D, et al.
**摘要**：该研究开发了靶向CLEC9A的单克隆抗体，证明其可将抗原特异性递送至人CD141+树突状细胞，显著增强抗肿瘤T细胞反应，为癌症疫苗设计提供了新策略。
2. **文献名称**：*Antibody targeting of CLEC9A directs antigens to cross-presenting dendritic cells and promotes potent CD8+ T cell responses*
**作者**：Caminschi I, et al.
**摘要**：研究显示，CLEC9A抗体通过结合树突状细胞表面的CLEC9A受体，有效促进抗原交叉呈递，并在小鼠模型中诱导强效的CD8+ T细胞应答，显示出抗病毒和抗肿瘤潜力。
3. **文献名称**：*CLEC9A-directed antibodies induce durable antitumor immunity by engaging human dendritic cell subsets*
**作者**：Loureiro LR, et al.
**摘要**：该文献报道了一种新型抗CLEC9A抗体偶联平台，通过靶向肿瘤相关抗原激活树突状细胞亚群，在临床前模型中显著抑制肿瘤生长并延长生存期。
注：以上文献为示例，实际引用时需核对具体发表信息及原文内容。
CD370. also known as CLEC9A (C-type lectin domain family 9 member A), is a transmembrane protein belonging to the C-type lectin receptor family. It is predominantly expressed on a subset of dendritic cells (DCs), particularly conventional type 1 DCs (cDC1), and plays a critical role in immune recognition and antigen presentation. CLEC9A recognizes filamentous actin exposed on damaged or necrotic cells, functioning as a sensor of cell death. This interaction facilitates cross-presentation of antigens to CD8+ T cells, linking innate and adaptive immunity.
CD370 antibodies are valuable tools for studying immune responses, particularly in infection, cancer, and autoimmune diseases. They are used to block or activate CLEC9A signaling, helping elucidate its role in DC maturation, cytokine production, and T-cell activation. In therapeutic contexts, CD370-targeting antibodies are explored for vaccine adjuvants or targeted drug delivery to cDC1s to enhance antitumor immunity. Some antibody formats (e.g., antibody-drug conjugates or bispecific antibodies) aim to direct antigens to CLEC9A+ DCs, optimizing immune activation.
Research also investigates CLEC9A's involvement in maintaining immune tolerance, as its deficiency may correlate with autoimmune disorders. CD370 antibodies thus serve both diagnostic and therapeutic purposes, bridging fundamental immunology and clinical applications.
×
